Aayush Agrawal, trustee of the Aayush Agrawal Trust, has released a pledge on 17,36,353 equity shares of Ajanta Pharma Limited. The promoter cited loan repayment as the reason for the release, reducing the encumbered portion of his holding.

The disclosure was filed with the Bombay Stock Exchange and the National Stock Exchange on September 16, 2026, in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Release Details

The pledge release was executed across multiple lenders between September 11 and September 15, 2026. Prior to this event, the Aayush Agrawal Trust held 1,41,12,924 shares, representing 11.29% of the total share capital, with 1,34,76,924 shares (10.79%) already encumbered.

Following the release, the total number of encumbered shares held by the trust stands at 1,17,40,571, which is 9.40% of the total share capital.

Lender-wise Breakdown

The table below details the specific pledge releases made to various financial institutions:

Promoter Holding Status

The disclosure also provides an overview of the broader promoter group's holdings as of the reporting date. While Aayush Agrawal reduced his pledged stake, other promoters maintained their existing encumbrance levels.

• Gabs Investments Pvt Ltd holds 1,25,88,393 shares (10.07%), with 27,70,000 shares (2.22%) remaining encumbered.
• Ravi P Agrawal, trustee of Ravi Agrawal Trust, holds 1,27,92,904 shares (10.24%), with 14,73,390 shares (1.18%) encumbered.
• Yogesh M Agrawal and Rajesh M Agrawal, trustees of their respective trusts, hold 1,80,78,147 and 1,80,78,148 shares respectively, with no shares currently encumbered.

What the Numbers Show

The release of pledge by Aayush Agrawal significantly lowers the concentration of risk associated with his personal borrowing against company stock. By reducing the encumbered portion from 10.79% to 9.40% of the total share capital, the promoter has improved the liquidity profile of his holding. This reduction suggests a deleveraging effort or successful debt servicing, thereby stabilizing the promoter's stake security relative to the total outstanding equity.

Ajanta Pharma will host one-on-one meetings with analysts and institutional investors on two dates in September 2026. The sessions are scheduled for September 16 in New Delhi and September 28 in Mumbai.

The company disclosed the schedule pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Gaurang Shah, Senior Vice President and Company Secretary, confirmed the dates on August 31, 2026.

Meeting Schedule

Both engagements are classified as one-on-one meetings. The company noted that the schedule is subject to change due to exigencies on either side.

Discussion Scope

Ajanta Pharma confirmed that discussions during these meetings will be strictly based on already published information. The firm did not disclose any new financial data or operational updates in this intimation.